UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

OP0228 EFFICACY AND SAFETY OF RISANKIZUMAB FOR ACTIVE PSORIATIC ARTHRITIS, INCLUDING PATIENTS WITH INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGIC THERAPIES: 24-WEEK RESULTS FROM THE PHASE 3, RANDOMIZED, DOUBLE-BLIND, KEEPSAKE 2 TRIAL

Annals of the rheumatic diseases, 2021-06, Vol.80 (Suppl 1), p.138-139

2021

Volltextzugriff (PDF)

L’aprémilast améliore l’état des patients atteints du rhumatisme psoriasique de forme oligoarticulaire : analyse principale de l’essai thérapeutique contrôlé vs placebo FOREMOST

Revue du rhumatisme (Ed. française : 1993), 2023-12, Vol.90, p.A190

2023

Volltextzugriff (PDF)

Secukinumab after anti-tumour necrosis factor-α therapy: a phase III study in active rheumatoid arthritis

Scandinavian journal of rheumatology, 2018-07, Vol.47 (4), p.276-281

2018

Volltextzugriff (PDF)

AB0743 Secukinumab Improves Multiple Parameters of Disease Activity in Subjects with Active Ankylosing Spondylitis Through 52 Weeks of Subcutaneous Therapy: Data From the Phase 3 Measure 2 Study

Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.1147-1147

2015

Volltextzugriff (PDF)

SAT0562 Long-Term (104-Week) Efficacy and Safety of Apremilast Monotherapy in Dmard-Naïve Patients with Psoriatic Arthritis: A Phase 3, Randomized, Controlled Trial and Open-Label Extension (Palace 4)

Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.863-864

2015

Volltextzugriff (PDF)

SAT0377 Long-Term Safety and Tolerability of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: A Phase 3, Randomized, Controlled Trial

Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.730-730

2014

Volltextzugriff (PDF)

SAT0389 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, is Associated with Long-Term (52-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Results from the Palace 4 Phase 3, Randomized, Controlled Trial

Annals of the rheumatic diseases, 2014-06, Vol.73 (Suppl 2), p.735-735

2014

Volltextzugriff (PDF)

OP0024 Safety and efficacy of SBI-087 in subjects with active rheumatoid arthritis in a phase 2 randomized, double-blind, placebo-controlled study

Annals of the rheumatic diseases, 2013-06, Vol.71 (Suppl 3), p.60-61

2013

Volltextzugriff (PDF)

L’aprémilast en monothérapie utilisé comme premier traitement systémique chez les patients naïfs de DMARD atteints de rhumatisme psoriasique actif : résultats du traitement à 3 ans

Revue du rhumatisme (Ed. française : 1993), 2016-11, Vol.83, p.A249-A249

2016

Volltextzugriff (PDF)

A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: The Treatment of Early Aggressive Rheumatoid Arthritis trial

Arthritis & rheumatology (Hoboken, N.J.), 2012-09, Vol.64 (9), p.2824-2835

2012

Volltextzugriff (PDF)

OP0115 EFFICACY AND SAFETY OF ABBV-3373, A NOVEL ANTI-TNF GLUCOCORTICOID RECEPTOR MODULATOR ANTIBODY DRUG CONJUGATE, IN PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS DESPITE METHOTREXATE THERAPY: A PHASE 2A PROOF OF CONCEPT STUDY

Annals of the rheumatic diseases, 2021-06, Vol.80 (Suppl 1), p.64-64

2021

Volltextzugriff (PDF)

POS1080 CHARACTERIZATION OF JOINT DISTRIBUTION AND DISEASE BURDEN IN PATIENTS WITH EARLY OLIGOARTICULAR PSORIATIC ARTHRITIS: RESULTS FROM THE ONGOING FOREMOST STUDY

Annals of the rheumatic diseases, 2022-06, Vol.81 (Suppl 1), p.865-866

2022

Volltextzugriff (PDF)

POS1036 EFFICACY AND SAFETY OF RISANKIZUMAB (RZB) FOR ACTIVE PSORIATIC ARTHRITIS (PsA): 52-WEEK RESULTS FROM KEEPsAKE 2

Annals of the rheumatic diseases, 2022-06, Vol.81 (Suppl 1), p.832-832

2022

Volltextzugriff (PDF)

POS0655 LONG-TERM SAFETY AND EFFICACY OF UPADACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS: 3-YEAR RESULTS FROM THE SELECT-EARLY STUDY

Annals of the rheumatic diseases, 2021-06, Vol.80 (Suppl 1), p.568-569

2021

Volltextzugriff (PDF)

THU0195 INCIDENCE AND RISK OF VENOUS THROMBOEMBOLIC EVENTS AMONG PATIENTS WITH RHEUMATOID ARTHRITIS ENROLLED IN THE UPADACITINIB SELECT CLINICAL TRIAL PROGRAM

Annals of the rheumatic diseases, 2020-06, Vol.79 (Suppl 1), p.317-318

2020

Volltextzugriff (PDF)

Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial

Annals of the rheumatic diseases, 2011-01, Vol.70 (1), p.39-46

2011

Volltextzugriff (PDF)

T cell receptor V gene usage by human T cells stimulated with the superantigen streptococcal M protein

The Journal of experimental medicine, 1991-07, Vol.174 (1), p.285-288

1991

Volltextzugriff (PDF)

Secukinumab after anti-tumour necrosis factor-α therapy: a phase III study in active rheumatoid arthritis

Scandinavian journal of rheumatology, 2018-02, p.1

2018

Volltextzugriff (PDF)

AB0943 Sustained improvements with up to 104 weeks of apremilast monotherapy in biologic-naÏve subjects with active psoriatic arthritis: results from a phase 3b, randomised, controlled trial

Annals of the rheumatic diseases, 2018-06, Vol.77 (Suppl 2), p.1596

2018

Volltextzugriff (PDF)

AB0905 Long-term (5-YEAR) efficacy and safety of apremilast monotherapy in dmard-naÏve subjects with active psoriatic arthritis

Annals of the rheumatic diseases, 2018-06, Vol.77 (Suppl 2), p.1576

2018

Volltextzugriff (PDF)

THU0422 Apremilast Monotherapy as The First Systemic Treatment in DMARD-Naïve Patients with Active Psoriatic Arthritis: 3-Year Treatment Results

Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.342-342

2016

Volltextzugriff (PDF)

OP0219 Early onset of efficacy with apremilast monotherapy in biologic-naÏve patients with active psoriatic arthritis: a phase 3b, randomized, controlled trial

Annals of the rheumatic diseases, 2017-06, Vol.76 (Suppl 2), p.143

2017

Volltextzugriff (PDF)

The Cocaine Body-Packer Syndrome: Evaluation of a Method of Contrast Study of the Bowel

Journal of forensic sciences, 1990-03, Vol.35 (2), p.345-355

1990

Volltextzugriff (PDF)

Extraosseous uptake of Tc-99m HDP in muscular dystrophy

Clinical nuclear medicine, 2000-02, Vol.25 (2), p.135

2000

Volltextzugriff (PDF)

Evidence for a streptococcal superantigen-driven process in acute guttate psoriasis

The Journal of clinical investigation, 1995-11, Vol.96 (5), p.2106-2112

1995

Volltextzugriff (PDF)

1 – 25 von 93

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(67)
Mit Volltextzugriff
(63)

Publikationsform

Artikel
(88)
Reviews
(3)
Berichte
(2)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

OP0228 EFFICACY AND SAFETY OF RISANKIZUMAB FOR ACTIVE PSORIATIC ARTHRITIS, INCLUDING PATIENTS WITH INADEQUATE RESPONSE OR INTOLERANCE TO BIOLOGIC THERAPIES: 24-WEEK RESULTS FROM THE PHASE 3, RANDOMIZED, DOUBLE-BLIND, KEEPSAKE 2 TRIAL

L’aprémilast améliore l’état des patients atteints du rhumatisme psoriasique de forme oligoarticulaire : analyse principale de l’essai thérapeutique contrôlé vs placebo FOREMOST

Secukinumab after anti-tumour necrosis factor-α therapy: a phase III study in active rheumatoid arthritis

AB0743 Secukinumab Improves Multiple Parameters of Disease Activity in Subjects with Active Ankylosing Spondylitis Through 52 Weeks of Subcutaneous Therapy: Data From the Phase 3 Measure 2 Study

SAT0562 Long-Term (104-Week) Efficacy and Safety of Apremilast Monotherapy in Dmard-Naïve Patients with Psoriatic Arthritis: A Phase 3, Randomized, Controlled Trial and Open-Label Extension (Palace 4)

SAT0377 Long-Term Safety and Tolerability of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: A Phase 3, Randomized, Controlled Trial

SAT0389 Apremilast, an Oral Phosphodiesterase 4 Inhibitor, is Associated with Long-Term (52-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Results from the Palace 4 Phase 3, Randomized, Controlled Trial

OP0024 Safety and efficacy of SBI-087 in subjects with active rheumatoid arthritis in a phase 2 randomized, double-blind, placebo-controlled study

L’aprémilast en monothérapie utilisé comme premier traitement systémique chez les patients naïfs de DMARD atteints de rhumatisme psoriasique actif : résultats du traitement à 3 ans

A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: The Treatment of Early Aggressive Rheumatoid Arthritis trial

OP0115 EFFICACY AND SAFETY OF ABBV-3373, A NOVEL ANTI-TNF GLUCOCORTICOID RECEPTOR MODULATOR ANTIBODY DRUG CONJUGATE, IN PATIENTS WITH MODERATE TO SEVERE RHEUMATOID ARTHRITIS DESPITE METHOTREXATE THERAPY: A PHASE 2A PROOF OF CONCEPT STUDY

POS1080 CHARACTERIZATION OF JOINT DISTRIBUTION AND DISEASE BURDEN IN PATIENTS WITH EARLY OLIGOARTICULAR PSORIATIC ARTHRITIS: RESULTS FROM THE ONGOING FOREMOST STUDY

POS1036 EFFICACY AND SAFETY OF RISANKIZUMAB (RZB) FOR ACTIVE PSORIATIC ARTHRITIS (PsA): 52-WEEK RESULTS FROM KEEPsAKE 2

POS0655 LONG-TERM SAFETY AND EFFICACY OF UPADACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS: 3-YEAR RESULTS FROM THE SELECT-EARLY STUDY

THU0195 INCIDENCE AND RISK OF VENOUS THROMBOEMBOLIC EVENTS AMONG PATIENTS WITH RHEUMATOID ARTHRITIS ENROLLED IN THE UPADACITINIB SELECT CLINICAL TRIAL PROGRAM

Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial

T cell receptor V gene usage by human T cells stimulated with the superantigen streptococcal M protein

Secukinumab after anti-tumour necrosis factor-α therapy: a phase III study in active rheumatoid arthritis

AB0943 Sustained improvements with up to 104 weeks of apremilast monotherapy in biologic-naÏve subjects with active psoriatic arthritis: results from a phase 3b, randomised, controlled trial

AB0905 Long-term (5-YEAR) efficacy and safety of apremilast monotherapy in dmard-naÏve subjects with active psoriatic arthritis

THU0422 Apremilast Monotherapy as The First Systemic Treatment in DMARD-Naïve Patients with Active Psoriatic Arthritis: 3-Year Treatment Results

OP0219 Early onset of efficacy with apremilast monotherapy in biologic-naÏve patients with active psoriatic arthritis: a phase 3b, randomized, controlled trial

The Cocaine Body-Packer Syndrome: Evaluation of a Method of Contrast Study of the Bowel

Extraosseous uptake of Tc-99m HDP in muscular dystrophy

Evidence for a streptococcal superantigen-driven process in acute guttate psoriasis

Suchergebnisse filtern